Taysha Gene Therapies, Inc. - Common Stock (TSHA)

Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy.

On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities

These stocks are making the most noise in today's session. Stay tuned for the latest updates!

Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program.

Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients.

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.